達仁堂(600329.SH):擬轉讓天津史克12%股份
格隆匯4月15日丨達仁堂(600329.SH)公佈,公司擬分別向赫力昂(中國)有限公司、Haleon
CH
SARL轉讓所持有的中美天津史剋制藥有限公司4.6%股權、7.4%股權,交易價格分別為622,328,888.89元人民幣、1,001,137,777.78元人民幣。經初步測算,該項交易預計影響公司當期投資收益約15.4億元人民幣。
本次交易充分體現了公司投資於天津史克的價值,交易價格符合市場水平且相比於資產評估價值有35%的溢價。本次交易可為公司股東帶來可觀的財務收益,經公司按2024年12月31日為交易基準日初步測算,以本次交易股權轉讓收入約16.23億元,減去史克投資賬面價值後,預計影響當期投資收益約15.4億元,預計增加交易發生會計年度所得税後淨利潤約13億元。本次交易符合公司聚焦主業的發展思路,有利於增加公司現金流入,交易獲得的資金可用於公司業務擴張,包括但不限於有戰略意義標的併購項目、研發項目、新品開發與市場拓展項目、營運資金及一般公司用途等等。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.